Esperion Therapeutics (NASDAQ:ESPR) Stock Price Up 8.7% – Time to Buy?

Esperion Therapeutics, Inc. (NASDAQ:ESPR)’s stock price was up 8.7% during mid-day trading on Friday . The company traded as high as $2.76 and last traded at $2.76. Approximately 2,417,710 shares changed hands during trading, a decline of 60% from the average daily volume of 6,116,351 shares. The stock had previously closed at $2.54.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Needham & Company LLC decreased their target price on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Wednesday.

Esperion Therapeutics Stock Performance

The company has a market capitalization of $551.70 million, a price-to-earnings ratio of -4.38 and a beta of 0.96. The firm has a 50-day simple moving average of $2.11 and a two-hundred day simple moving average of $2.16.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. BOKF NA purchased a new position in Esperion Therapeutics in the 2nd quarter valued at approximately $26,000. Xponance Inc. acquired a new stake in shares of Esperion Therapeutics in the second quarter valued at $28,000. Traphagen Investment Advisors LLC purchased a new position in Esperion Therapeutics in the third quarter valued at $27,000. National Bank of Canada FI grew its stake in Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 10,225 shares in the last quarter. Finally, Sivia Capital Partners LLC purchased a new stake in Esperion Therapeutics during the 2nd quarter worth about $44,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.